JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
TB-500 and BPC-157 are synthetic peptide fragments based on larger endogenous peptide sequences. In biochemical research settings, these peptides are referred as representative compounds of exploring the signaling framework associated with peptides, molecular interaction modalities and pathway-associated regulatory hierarchy in controlled analytical environment.
Experimental use of TB-500 and BPC-157, whether independently or in combination, is limited to laboratory-based evaluation of signalling network convergence, peptide stability parameters, and interaction dynamics within defined in-vitro systems. Such investigations focus on molecular correlation, pathway mapping, and signal propagation characteristics without attribution to functional, physiological, or organism-level outcomes.
The TB-500 and BPC-157 combination offered on our website is classified strictly as a research material. It is intended solely for laboratory, analytical, or educational investigation. These compounds are not approved for human or animal use, and no clinical, diagnostic, therapeutic, or biological applications are stated or implied.
BPC-157 has been referenced in experimental and analytical settings as a synthetic peptide fragment utilized for examining peptide–protein interaction patterns and signalling architecture within connective-tissue–derived cellular frameworks. In laboratory systems, connective-tissue cell models are frequently employed to evaluate cytoskeleton-adjacent signalling organisation, extracellular structural components, and gene-level regulatory markers associated with actin-linked molecular assemblies.
Observations reported in controlled environments describe alterations in signalling markers and transcriptional profiles associated with actin-related regulatory elements following peptide exposure, without attribution to functional or organism-level outcomes [1].
TB-500 has similarly been incorporated into experimental models as a molecular reference compound for studying actin-associated binding behaviour, filament organisation parameters, and cytoskeletal signalling topology. Analytical investigations focus on characterising interactions between TB-500 and actin-related molecular components under defined in-vitro conditions, with emphasis on signalling correlation and structural interaction mapping rather than biological performance or effect [2].
TB-500 and BPC-157 have been utilized in laboratory research as comparative peptide tools for analysing signalling pathways that are adjacent to endothelial-associated molecular markers, including pathways commonly referenced in vascular signalling literature. Experimental evaluations in controlled systems have examined changes in pathway-level signalling intermediates, including factors associated with growth-signal transduction, for the purpose of pathway mapping and regulatory cross-talk analysis rather than functional interpretation [3,4].
Investigations involving combined peptide exposure are limited to describing signalling network overlap, divergence, and interaction dynamics within reductionist experimental models. These analyses are conducted strictly to advance understanding of molecular signalling architecture and do not imply physiological, regenerative, or adaptive outcomes.
At Element CRP, the TB-500 and BPC-157 blend for sale is classified exclusively as a research material. It is supplied solely for laboratory, analytical, and investigative research purposes.
These compounds are not approved for human or animal use, and no clinical, diagnostic, therapeutic, or consumptive applications are stated or implied. Access is restricted to qualified research professionals only.
The BPC-157 / TB-500 blend combines two distinct synthetic peptides at 2mg each per vial: BPC-157 (a 15-amino-acid pentadecapeptide engaging growth factor receptor pathways) and TB-500 (a 17-residue thymosin beta-4 active fragment with actin-binding properties). The combined preparation supports comparative cell biology research and combined-exposure pharmacology investigations.
Cell-based research using the BPC-157 / TB-500 blend examines convergent and divergent pathway engagement of the two peptides — VEGFR2/FAK signalling for BPC-157 alongside G-actin binding and integrin pathway modulation for TB-500. Combined-exposure datasets in endothelial and fibroblast cell models capture additive and synergistic effects on PI3K/Akt downstream signalling.
Element CRP supplies this product at 2mg ea / 4mg total per vial. USA-manufactured via solid-phase peptide synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitution with bacteriostatic water required. Store lyophilised at -20°C; stable for 24 months.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
